BioArctic: Long-term health outcomes for lecanemab using sim

STOCKHOLM, April 4, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today announced that its partner Eisai has published an article about long-term health outcomes of anti-amyloid-beta

Related Keywords

Japan , China , Sweden , Stockholm , Uppsala , Uppsala Lan , Swedish , Oskar Bosson , Translational Research Clinical Interventions , Alzheimer Clinical Trial Consortium , National Medical Products Administration , National Institute On , European Medicines Agency , Ministry Of Health , Nasdaq , Washington University School Of Medicine , Vp Communications , National Institutes Of Health , Uppsala University , Drug Administration , Alzheimer Network Trials Unit , Devices Agency , Advisory Committee , Biologics License Application , Priority Review , Prescription Drug User Fee Act , Medical Devices Agency , Brand Name , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Commercialization Agreement , Nasdaq Stockholm Large Cap , Translational Research , Bioarctic , Song , Term , Health , Outcomes , Lecanemab , Sing , Simulation , Model , Hase , Clarity , Data , Published ,